Shijiazhuang pharmaceutical group recruitment

General situation of calculus medicine

Shijiazhuang Pharmaceutical Group Co., Ltd. was established by Hebei Pharmaceutical Group Corporation and Shijiazhuang No.1 Pharmaceutical Group Corporation on1June 5438+August 2 1 97. It is the first super-large pharmaceutical enterprise in the national pharmaceutical industry and one of the large pillar enterprise groups in Hebei Province.

Unacon's total assets exceed 8 billion yuan and its employees are about10.5 million. It has more than ten wholly-owned or holding subsidiaries such as Zhongrun, Weisheng, Zhongnuo, Zhongrun Inner Mongolia and Enbipu. Among them, China Pharmaceutical Group Co., Ltd. (hereinafter referred to as "China Pharmaceutical"), a holding subsidiary of Hong Kong, is the first overseas listed company in China pharmaceutical industry and one of the largest pharmaceutical listed companies in Hong Kong at present. In 2003 and 2004, China Pharmaceuticals was awarded as one of the top listed companies in Asia 100 with a turnover of less than 1 00 million dollars by the world-famous Forbes magazine for two consecutive years. "China Pharmaceutical" has been listed on the Hong Kong Stock Exchange for more than ten years, raised more than 2 billion yuan from the international capital market, and invested in a series of key projects, such as vitamin C, 7-ACA, cephalosporin, new drug Enbipur and antibiotic relocation, which greatly promoted the rapid development of the pharmaceutical industry in Hebei Province and even the whole country.

Global professional API suppliers

Unocon aims to build an excellent pharmaceutical brand in China and is committed to becoming an excellent raw material supplier in the world. Our company supplies vitamin C, vitamin B 12, 7-ACA, 6APA, amoxicillin, ampicillin, industrial salt of penicillin, procaine penicillin, azithromycin, ranitidine and so on. It plays an important role in the international market and is also an important supplier of antipyretic and analgesic raw material drugs in China. The annual production capacity of vitamin C reaches 30,000 tons, and the annual production capacity of penicillin industrial salt reaches10.5 million tons, ranking third in the country. The production capacity of 6-APA and amoxicillin ranks first in China, and the production scale of 7ACA reaches 1.600 tons/year, ranking first in the world.

* * * The company has 16 API workshops, which have passed the GMP certification of China State Food and Drug Administration and are currently undergoing FDA/COS certification. Products include vitamin C, vitamin B 12, amoxicillin, 7-ACA, penicillin sodium, ranitidine, tramadol hydrochloride and so on. Caffeine has passed COS certification in Europe.

The world's largest venture capital production base

Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd. is a wholly-owned subsidiary of China Pharmaceutical Group Investment Co., Ltd. controlled by Unacon. Vitamin C and its series products, such as sodium VC, calcium VC, coated VC and VC granules, have an annual production capacity of 30,000 tons and are widely used in medicine, food, feed, health care products and other fields. 80% products are exported to more than 30 countries and regions such as Europe, America, Japan, Australia and Southeast Asia.

Unacon's vinyl chloride production capacity has increased from 3000 tons to 30000 tons per year. Its transformation and expansion is not only quantitative change, but also qualitative change. The factory, equipment and other hardware facilities are designed and constructed in strict accordance with the internationally accepted FDA and COS standards, which greatly improves the internal quality and technical level of vitamin C products and creates conditions for entering the international pharmaceutical vitamin C market and expanding market share.

China western antibiotic pharmacy industrial park

Using advanced and applicable technologies to transform and upgrade traditional industries.

With its decisive and keen strategic vision, Unocal resolutely decided to invest 10 billion yuan in Inner Mongolia Autonomous Region in the west of China, set up the first phase of the series of antibiotic products with an annual output of 10000 tons, and set up China Medicine (listed company in Shijiazhuang) Inner Mongolia Co., Ltd., covering an area of 1000 mu with a construction area of 65438+. The commissioning of this project is also a successful symbol of Unocom's giving full play to its own advantages in technology, capital and market, implementing the strategy of "moving westward" and starting a second business.

In this promising land at the southern foot of Daqing Mountain, a modern antibiotic production base has sprung up in just ten months, and the stone medicine people have interpreted the work style of "being rigorous and realistic, determined to win" with their own actions.

Preparation of drugs

Unocon is an important manufacturer and operator of chemical products and traditional Chinese medicine products in China. Its huge preparation family composition is the result of the company's continuous research and development and production for 70 years.

The annual production capacity of Younuokang preparation is 2.4 billion powder injections, 65.438+0.2 billion water needles, 5 billion tablets, 5 billion capsules and 400 million soft capsules. The varieties of preparations involve antibiotics, vitamins, cardiovascular and cerebrovascular diseases, antipyretic and analgesic diseases, digestive system diseases, psychotropic drugs, narcotic drugs and other system fields, with a complete range and wide radiation range, which is second to none in the industry.

Unacon attaches importance to scientific research and market development. In recent years, the group has attracted a large number of high-quality scientific research talents with generous treatment and good working environment, and has successively developed new drugs from more than 40 countries, such as azithromycin, alendronate sodium, enalapril and acemetacin.

Unocal provides several kinds of drugs related to the national economy and people's livelihood for the society in any medical field. Since its establishment, the company has been adhering to the development principle of "science and technology lead pharmacy", providing products with the qualification rate of 100%, serving the public and benefiting mankind.